SpyGlass Pharma, Inc. cash flow statement SGP

In fiscal 2025, which ended Dec 31, 2025, SpyGlass Pharma, Inc. used $32.7 million of cash from operations. It spent $789,000 on capital expenditures. Free cash flow was negative, at -$33.5 million. The company returned $1.4 million in share buybacks to shareholders.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
Operating
Depreciation and amortization
—
1
Stock-based compensation
—
3
Operating cash flow
—
-33
Investing
Capital expenditures
—
1
Investing cash flow
—
-12
Financing
Stock buybacks
—
1
Financing cash flow
—
125
Change in cash
Net change in cash
—
80
Free cash flow
—
-33
Per share
Free cash flow per share
—
-15.11
Shareholder returns
Returned to shareholders
—
1
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
SGP (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Irvine, CA
SEC filer status
, Emerging growth company
SEC CIK
1778922
Former names
SpyGlassPharma, Inc. (until Jun 5, 2025); SpyGlass Ophthalmics, Inc. (until Jan 5, 2021)

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.